1. A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing sarcoma models.
A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing sarcoma models. Combination A (temozolomide 30 mg/kg for 5 days; talazoparib 0.1 mg/kg twice daily for 5 days); combination B (temozolomide 12 mg/kg for 5 days; talazoparib 0.25 mg/kg twice daily for 5 days). Graphs show growth of individual tumors in SCID mice. B, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “insensitive” Ewing sarcoma models. Combination A (temozolomide 30 mg/kg for 5 days; talazoparib 0.1 mg/kg twice daily for 5 days); combination B (temozolomide 12 mg/kg for 5 days; talazoparib 0.25 mg/kg twice daily for 5 days). Graphs show growth of individual tumors in SCID mice.
Malcolm A. Smith et al. Clin Cancer Res 2015;21:
©2015 by American Association for Cancer Research